BJGMC Clinical Research Team Exceeds 6,000 Participant Enrollments in 4 Years

Date: 08/03/2018

The Indo-JHU Clinical Research partnership at Byramjee Jeejeebhoy Government Medical College (BJGMC) in Pune, India, is on an enrollment roll. The team has enrolled more than 6,000 participants in clinical trials and epidemiological studies, with approximately 1,200 during the last year. Indo-JHU research is led by Dr. Vidya Mave, Dr. Nishi Suryavanshi, and Dr. Nikhil Gupte in collaboration with BJGMC Deans Ajay Chandanwale and Sameer Joshi, and several heads of department, including Drs. Sangle of Medicine, Bhosale of Obstetrics and Gynecology, Bharadwaj of Microbiology, Kinikar of Pediatrics, and Gaikwad of Chest Medicine.

According to BJGMC Clinical Research Site (CRS) Director Dr. Vidya Mave, “The growth in the numbers of studies and participants has presented challenges that the team has really risen to. Among contributions of more than dedicated 150 team members, we owe much of our participant recruitment and management success to effective community outreach led by Savita Kanade and truly impressive coordination of studies by Dr. Nishi Suryavanshi. The CRS team is making a difference, and we take pride in our site’s contributions.”

Access Full Article

Clinical Trials

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

A5302:  BioBank for Surrogate Marker Research for TB...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

Read More

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More